Bladder symptoms during IVF often reflect hormonal and pelvic floor changes, not infection, according to Aleece Fosnight, MSPAS, PA-C.
News|Articles|October 2, 2025
FDA news recap in benign urology for Q3 2025
Author(s)Hannah Clarke
Fact checked by: Benjamin P. Saylor, Strategic Content Lead
Take a look back at the notable regulatory decisions in benign urology between July and September.
Advertisement
Advertisement
The landscape in benign urology continues to see steady progress. In Q3 of 2025, this progress was marked by key priority review designations, which set the stage for decisions in hypoactive sexual desire disorder and uncomplicated gonorrhea in the months ahead. Q3 also welcomed approvals for novel devices for urge urinary incontinence and cystoscopy, highlighting the continued technologic advances that are transforming care.
Related to this article
A national survey found US hospitals expanded CAUTI prevention over 20 years, but use of key catheter-removal strategies remains variable.
The assay is designed to enable faster pathogen identification and susceptibility testing to guide UTI management.
Rezūm improved symptoms and quality of life at 1 year vs combination pharmacotherapy in sexually active men with BPO while preserving sexual function.
Sri Sivalingam, MD, discusses how suction-based technologies are improving stone clearance and raising expectations for ureteroscopic stone treatment.
Abraham Morgentaler, MD, reviews evidence showing no association between testosterone therapy and prostate cancer risk and explains the saturation model of androgen action.
Based on these results, the trial protocol has been amended to move enrollment earlier in the course of disease progression.
Mark D. Tyson, II, MD, MPH, reviews emerging bladder-sparing therapies for NMIBC, highlighting cretostimogene data, treatment sequencing, and the need for comparative trials.
Advertisement
Advertisement